


## RORyt inverse agonist 30

|                    |   |
|--------------------|---|
| Cat. No.:          | HY-147533   |
| CAS No.:           | 1445901-41-6  |
| Molecular Formula: | C <sub>24</sub> H <sub>31</sub> N <sub>3</sub> O <sub>3</sub> S                           |
| Molecular Weight:  | 441.59  |
| Target:            | ROR   |
| Pathway:           | Metabolic Enzyme/Protease   |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                           |   |
|---------------------------|---|
| Description               | RORyt inverse agonist 30 (Compound 1) is a potent RORyt inverse agonist with the IC <sub>50</sub> of 46 nM. Targeting the nuclear receptor RORyt is effective in autoimmune disorders <sup>[1]</sup> .  |
| IC <sub>50</sub> & Target | RORyt<br>46 nM (IC <sub>50</sub> )  |
| In Vitro                  | RORyt inverse agonist 30 (compound 1) inhibits mouse Th17 cell differentiation with an IC <sub>50</sub> of 0.67 μM <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |
| In Vivo                   | RORyt inverse agonist 30 exhibits favorable pharmacokinetics profiles with T <sub>1/2</sub> of 2.3 min, CL <sub>int</sub> of 612 μL/min/mg and CL <sub>int(liver)</sub> of 2423.5 mL/min/kg <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### REFERENCES

[1]. Nannan Sun, et al. Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases. Eur J Med Chem. 2020 Feb 1;187:111984.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA